🔬
Novo Nordisk Integrates OpenAI for Obesity Drugs
Novo Nordisk will integrate OpenAI’s AI across the company. The goal is to speed up development of new obesity drugs. This partnership leverages AI for faster R&D.
Search
Tag: #pharma11 results
FDA Approves First Oral PCSK9 Inhibitor for Cholesterol
Merck's Enlicitide (MK-0616) has been approved by the FDA as the first oral PCSK9 inhibitor, offering a convenient alternative to injectable antibody-based cholesterol treatments.
The Race for Next-Gen ADC Assets Begins
The pharmaceutical industry is entering a high-stakes competition to acquire and develop next-generation Antibody-Drug Conjugate (ADC) assets. This marks a critical moment for re-evaluating the value of these targeted therapies.
Novo Nordisk hit by $25m cyber-extortion attempt
A hacking group named FulcrumSec claims to have stolen 1.3 terabytes of data from Novo Nordisk. The company has refused to pay the $25 million ransom demand.
Amazon Launches AI for Drug Discovery
AWS launched Amazon Bio Discovery, an AI platform to accelerate early-stage drug discovery in pharma. It enables scientists to design and test novel drugs quickly and securely via complex computations.
Global Pharma Market Shift: GLP-1 Drugs Dominate Revenue
Q1 2026 financial reports reveal a major shift in the pharmaceutical industry, with GLP-1 metabolic drugs propelling Eli Lilly and Novo Nordisk to the top, while traditional giants struggle with patent cliffs.
Red Sun Pharma terminates Hepatitis C drug project
Red Sun Pharma has officially terminated its Class 1 chemical drug project for Hepatitis C. The decision follows concerns over high development risks and limited clinical significance.
🔬
Novartis Acquires Myricx Bio for $1.5 Billion
Novartis has agreed to acquire British biotech firm Myricx Bio to bolster its oncology pipeline. The deal focuses on experimental drug technology designed to target tumors precisely while sparing healthy cells.
Astellas cuts price of gastric cancer drug by 30%
Astellas Pharma has reduced the price of its Claudin18.2 targeted therapy, Zolbetuximab, by over 30% in China to compete with emerging local alternatives and secure a spot in the national medical insurance list.
💼
Eli Lilly's Strategy to Sustain Trillion-Dollar Growth
Eli Lilly has achieved a $1 trillion valuation driven by the success of Mounjaro and Zepbound. The company is now focused on diversifying its pipeline to avoid the typical boom-and-bust cycles seen in the pharmaceutical industry.